ORIGINAL ARTICLE |
|
Year : 2020 | Volume
: 25
| Issue : 1 | Page : 69 |
|
Study of T-cell immunoglobulin and mucin domain-3 expression profile in peripheral blood and bone marrow of human acute lymphoblastic leukemia patients
Narges Zargar Balajam1, Mahdi Shabani2, Mahmoud Aghaei1, Mansoureh Haghighi1, Farzad Kompani3
1 Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran 2 Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 3 Department of Hematology and Oncology, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Dr. Mahmoud Aghaei Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, P.O. Box: 81746-73461, Isfahan Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrms.JRMS_759_19
|
|
Background: Acute lymphoblastic leukemia (ALL) is a malignancy with aggressive tumors of immature lymphocytes. T-cell immunoglobulin and mucin-domain 3 (TIM-3) is a Type I transmembrane glycoprotein which is involved in cell proliferation. The objective of this research is to determine the TIM-3 expression in peripheral blood (PB) and bone marrow (BM) of 80 samples of normal and ALL patients. Materials and Methods: The amount of mRNA and protein of TIM-3 measured in the BM and PB the mononuclear layer of samples by real-time polymerase chain reaction and Western blotting. Results: Our findings indicated that relative mRNA expression of TIM-3 in PB and BM of the mononuclear layer of ALL patients was 1.7 and 5 times higher than normals, respectively. We also reported that the protein level of TIM-3 in mononuclear cells of ALL patients was 3.2-fold in BM and two-fold in PB more than normals. Conclusion: In conclusion, this study shows that TIM-3 increases in ALL patients, thus the expression of TIM-3 in tumor cells may be considered as a potential predictive factor in ALL patients, which needs to be explored in future.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|